Congress mandates pediatric cancer gets population-share of all federal cancer research funding
H.R. 6054 — Fairness to Kids with Cancer Act of 2025 · Filed by Brian Fitzpatrick (R-PA) · 6 cosponsors · Introduced Nov 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to dedicate a percentage of all cancer research funding to pediatric cancer research equal to the percentage of the U.S. population under age 18. Starting in fiscal year 2026, if children make up (for example) 22% of the population, then 22% of federal cancer research dollars must go to pediatric cancer research. The bill gives the President responsibility for ensuring this allocation happens.
Why we flagged it
The bill's sole operative mechanism is a mandatory reallocation of existing federal cancer research appropriations. It does not create new funding; it redistributes current dollars based on demographic proportion. This is a straightforward funding-priority directive, not a new program or regulatory change.
What the text implies
- The bill does not specify which agencies (NIH, NCI, etc.) must implement the reallocation or how they will adjust existing grants and commitments mid-stream.
- Using population proportion as the metric means pediatric cancer research funding will fluctuate annually with Census Bureau population estimates, creating budget uncertainty.
The full analysis lists 4 implications of this text.
Who stands to gain
pediatric cancer research institutions and hospitals; pediatric oncology researchers and academic medical centers; pharmaceutical and biotech companies developing pediatric cancer therapeutics